Home lifeDomestic services apparel Entertainment News Player community More

GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC

2025-01-26 GC Cell HaiPress

YONGIN,South Korea,Jan. 23,2025 -- GC Cell,a leading cell and gene therapy company,announced the successful completion of its first thought leadership symposium in Jakarta,Indonesia. The event was organized in collaboration with PT Bifarma Adiluhung (Bifarma),a pioneer in Indonesia's stem cell therapy sector,and showcased GC Cell's innovative cancer immunotherapy,Immuncell-LC.


Insights into Immuncell-LC's mechanisms of action,real-world treatment experiences,and clinical case studies were key focus areas of the symposium. Indonesian oncologists engaged with renowned Korean medical professionals experienced in applying the therapy in clinical trials,fostering fruitful in-depth discussions about its clinical potential.

"As the first-ever overseas event for a cell therapy created in Korea,this symposium marks is a significant milestone for the industry," said a GC Cell spokesperson. "By building trust and visibility in the Indonesian market,we are accelerating the global commercialization of Immuncell-LC and establishing it as a leading treatment option for cancer patients around the world."

Strengthening Global Partnerships

Since signing a licensing agreement with Bifarma in September 2024,GC Cell has been actively transferring the necessary technology to support local production and quality control. The six-month program,conducted at GC Cell's headquarters,is on track to enable Bifarma to launch Immuncell-LC in the Indonesian market by 2025.

A participant in the symposium commented,"This event provided a unique opportunity to understand the impact cell therapies can have on oncology in Indonesia,while underscoring the high level of interest among local healthcare providers. Immuncell-LC has the potential to transform cancer treatment here,and we are excited to see this unfold."

GC Cell's collaboration with Bifarma is part of its broader strategy to expand its presence in global markets,offering innovative cell therapies to improve patient outcomes across borders and establishing a competitive edge in the rapidly evolving global biotechnology landscape.


Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

Jewellery & Gem ASEAN Bangkok (JGAB) 2025: Connecting ASEAN's Gem and Jewellery Business to the Global Market

BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors

Acer Reports FY2024 Net Income of NT$5.54 Billion and NT$1.7 Cash Dividend Per Share

Ping An #1 in Brand Finance's Global Insurance Brand Value for 9th Year, Brand Value Reaches $33.6 Billion

LITEON Showcase Groundbreaking Energy Savings in Private 5G Network with NTT EAST at MWC 2025

2025 Global Sources Hong Kong Shows: Shaping the Future of Consumer Trends and Redefining Sourcing

©copyright2009-2020New York Fashion News    Contact Us  SiteMap